Evidence map›Paper›PMID 42103741›Full record

Trial reportNature communications2026

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.

Xiaowei Zhang, Ting Zhao, Midie Xu, Yanjing Guo, Qifeng Wang, Yanli Wang, Liangping Zhou, Silong Hu, Qinghua Xu, Xichun Hu and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04848597 (Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04848597 phase2unknown statusnot on this map

Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary (CUP)

TypeinterventionalSponsorFudan UniversityRan2021 to 2023Enrolled48ConditionsCancer of Unknown PrimaryArmsRecombinant humanized anti-PD-1 monoclonal antibody injection
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaowei Zhang *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ting Zhao *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Midie Xu *Department of Pathology and Biobank, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-1775-6608
Yanjing GuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qifeng WangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yanli WangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liangping ZhouDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Silong HuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qinghua XuThe Canhelp Genomics Research Center, Canhelp Genomics, Hangzhou, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. huxichun@shca.org.cn.ORCID http://orcid.org/0009-0008-4760-9637
Xin LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. jeanettexin@hotmail.com.
Zhiguo LuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. luozhiguo88@163.com.ORCID http://orcid.org/0000-0003-0389-2350

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fudan CUP-002 study (ClinicalTrials.gov identifier: NCT04848597), an investigator-initiated prospective trial, was designed to evaluate the efficacy and safety of an anti-PD-1 antibody in combination with nab-paclitaxel and bevacizumab as a second-line treatment for cancer of unknown primary (CUP). Between June 2, 2021, and April 19, 2024, 48 eligible patients were enrolled. At data cutoff (January 10, 2025), the median follow-up was 27.1 months (95% CI, 20.2 to 37.2). The objective response rate (ORR) was 54.2% (26/48; 95% CI, 40.3% to 67.4%), and the disease control rate (DCR) was 95.8% (46/48; 95% CI, 86.0% to 98.9%). The median progression-free survival (PFS) was 13.1 months (95% CI, 8.0 to 19.6), while the median overall survival (OS) was 25.1 months (95% CI, 14.6 to 29.5). Treatment-related adverse events (TRAEs) of any grade occurred in 46 patients (95.8%). The exploratory analysis identified systemic eosinophil counts as a prognostic biomarker for treatment response and survival outcomes in second-line setting for CUP. However, current experimental systems are unable to provide the established cell lines or animal models needed to investigate therapeutic mechanisms for CUP. Our present study demonstrated that an anti-PD-1 antibody plus nab-paclitaxel and bevacizumab was effective and well-tolerated in the second-line treatment for patients with CUP.Trial registration: ClinicalTrials.gov identifier: NCT04848597.

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabNeoplasms, Unknown PrimaryPaclitaxelProgrammed Cell Death 1 ReceptorAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalProspective StudiesTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsBevacizumabPaclitaxelPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID42103741
PMCPMC13376930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.